TST001 not checked
Transcenta Therapeutics (Hangzhou) Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TST001 will be administered by specified doses on specified day”In the company’s words, NCT04495296 on ClinicalTrials.gov
- Tested for
- Advanced Cancer (3 trials), Gastric Cancer (2 trials), Gastroesophageal-junction Cancer (2 trials), Pancreatic Cancer
- Main trialPhase 3
- “Gastric/GEJ adenocarcinomas are aggressive tumors with a high probability of death. Current treatment guidelines include two-drug cytotoxic chemotherapy with a fluoropyrimidine (mFOLFOX6: capecitabine or fluorouracil) and a platinum-based agent (CapOx: oxaliplatin or cisplatin). In addition, the FDA has approved nivolumab, a PD-1 checkpoint inhibitor, in combination with chemotherapy as first line treatment for advanced or metastatic gastric/GEJ cancer. TST001 is a recombinant humanized monoclonal antibody against Claudin 18.2 (a tumor marker found in gastric/GEJ cancer. In this study, the…”In the company’s words, NCT06093425 on ClinicalTrials.gov
Other drugs for Advanced Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up3
- 30 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 1 Oct 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 1 Oct 2029 | Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma | |
| Phase 1/2Active, not recruiting | 30 Jun 2027 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | |
| Phase 1/2Active, not recruiting | 30 Jun 2027 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026